| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 0.00% | 0.00% | — | — | — |
| Operating Margin | — | — | — | -37017.83% | -26146.55% | -19678.54% | -17331.51% | -18385.52% | -19972.62% | — | — | — |
| EBITDA Margin | — | — | — | -37014.58% | -26144.89% | -19677.60% | -17330.52% | -18383.19% | -19967.36% | — | — | — |
| Net Margin | — | — | — | -37378.50% | -25616.04% | -19497.87% | -17291.27% | -16715.52% | -20769.91% | — | — | — |
| Current Ratio | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 | 0.53 | 0.67 |
| Quick Ratio | 0.13 | 0.17 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 | 0.53 | 0.67 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -58.83% | -56.26% | -35.83% | -32.72% | -17.44% | -52.12% | -63.84% | -44.99% | -47.32% | -49.48% | 456.90% | 99.43% |
| ROA | -30.35% | -33.80% | -31.41% | -29.51% | -16.19% | -40.09% | -53.69% | -40.37% | -42.53% | -37.79% | -391.38% | -47.37% |
| Asset Turnover | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Book Value / Share | 6.10 | 10.42 | 0.60 | 0.70 | 1.22 | 0.86 | 1.21 | 2.60 | 4.00 | — | — | — |
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology, adjunct cancer care, stem cell therapy, and unique prescription products. Its diverse pipeline includes candidates targeting serious medical conditions, reflecting a commitment to advancing treatments that address critical unmet needs in healthcare. With a strategic emphasis on critical care and oncology-related therapeutics, Citius plays a significant role in the pharmaceutical industry by aiming to improve patient outcomes through novel drug development. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals leverages its clinical expertise to progress products through late-stage development toward commercialization.